Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Intradermal substance P as a challenge agent in healthy individuals.
Journal: Clinical and translational science
Published: February 23, 2023
First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: November 06, 2018
A population analysis of the DGAT1 inhibitor GSK3008356 and its effect on endogenous and meal-induced triglyceride turnover in healthy subjects.
Journal: Fundamental & clinical pharmacology
Published: October 31, 2018
A Phase 1 Randomized, Placebo-Controlled Trial With a Topical Inhibitor of Stearoyl-Coenzyme A Desaturase 1 Under Occluded and Nonoccluded Conditions.
Journal: Clinical pharmacology in drug development
Published: February 27, 2017
A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: February 19, 2015
Comparison of vestipitant with ondansetron for the treatment of breakthrough postoperative nausea and vomiting after failed prophylaxis with ondansetron.
Journal: British journal of anaesthesia
Published: December 10, 2014
Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist Vestipitant.
Journal: Clinical pharmacology in drug development
Published: January 09, 2014
Showing 1-7 of 7
Last Updated: 09/26/2026